In an article in the July 7 issue on monitoring adverse effects of
antipsychotics, it was noted that Pfizer Inc. is funding a large international
study known as the Ziprasidone Observational Study of Cardiac Outcomes. Two
details about the study were incorrect.
The study will assess the cardiovascular safety profile of Pfizer's Geodon
brand of ziprasidone compared with olanzapine (Eli Lilly's Zyprexa) only, not
several other antipsychotics.
The study is being led by Brian Strom, M.D., M.P.H., director of the Center
for Clinical Epidemiology and Biostatistics at the University of Pennsylvania
School of Medicine, not by John Kane, M.D. Kane is a participating researcher
in the study. ▪